WuXi Biologics works with Sino on first-in-class antibody

WuXi Biologics (HKEX: 2269) has signed a deal with Sino Biopharm (HKEX: 1177) to develop a first-in-class monoclonal antibody targeting an undisclosed indication.

The firm will provide integrated discovery services using a number of its platforms, including single B cell technology. WuXi provides end-to-end solutions for biologics development and manufacturing.

Sino is seeking to identify and optimize a lead antibody candidate for pre-clinical development. The company will hold exclusive rights to the MAb and oversee subsequent investigational new drug applications, clinical trials, and commercialization.